MedTrace Logo

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

NCT06089967 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-01-28

No results posted yet for this study

Summary

The purpose of this project is to collect body samples like blood and tissue and health information from people receiving immune-based treatment for cancer. The body samples and health information will be stored for future research to understand more about side effects related to immune-based treatments for cancer.

Conditions

  • Cancer
  • Immune-related Adverse Event

Interventions

OTHER

Medical chart review

Clinical data for all enrolled patients will be abstracted from the electronic medical record. This will include but will not be limited to patient demographics, primary disease (site, histology, histologic grade, staging system used, staging, molecular markers), prior cancer treatment, immunotherapy received, time of onset, treatment received for irAEs, and disease response to treatment. Clinical data will be collected for up to one year after discontinuation of cancer immunotherapy treatment.

Sponsors & Collaborators

Principal Investigators

  • Brent Hanks, MD PhD · Duke Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-05
Primary Completion
2024-12-06
Completion
2024-12-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06089967 on ClinicalTrials.gov